<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Carisoprodol" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Carisoprodol</book-part-id>
      <title-group>
        <title>Carisoprodol</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>1</month>
          <year>2017</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Cariprazine" document-type="chapter">Cariprazine</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Carmustine" document-type="chapter">Carmustine</related-object>
    </book-part-meta>
    <body>
      <sec id="Carisoprodol.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Carisoprodol.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Carisoprodol is a centrally acting muscle relaxant that has been in use for more than fifty years without significant evidence for causing hepatic injury.</p>
        </sec>
        <sec id="Carisoprodol.Background">
          <title>Background</title>
          <p>Carisoprodol (kar eye" soe proe' dol) is a carbamate derivative similar to meprobamate. Its mechanism of action as a muscle relaxant is unknown, but it is a sedative and may act centrally by modifying perception of pain without affecting pain reflexes. Carisoprodol is recommended for treatment of acute, painful disorders of the musculoskeletal system. Carisoprodol is available in 250 and 350 mg tablets in generic formulations and under the trade names of Soma, Carisoma, Sodol and Vanadom. Fixed combinations of carisoprodol with aspirin or codeine are also available. The recommended adult dosage is 250 to 350 mg three to four times daily for 2 to 3 weeks. Carisoprodol was approved for use in the United States in 1959 and is widely used with more than 10 million prescriptions filled yearly. It is available by prescription only and is classified as a Schedule IV agent, meaning that it has low potential for abuse and physical or psychological dependence and has an accepted medical usefulness. Common side effects include dizziness, drowsiness and headache. Overdose can cause progressive obtundation, coma, neuromuscular rigidity, myoclonus and seizures.</p>
        </sec>
        <sec id="Carisoprodol.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>There have been no adequate prospective studies demonstrating the rates of aminotransferase elevations on carisoprodol therapy or convincing case reports of clinically apparent liver injury due to carisoprodol. Thus, the hepatotoxic potential of this medication is low. It has been increasingly reported as a substance of abuse, taken in higher than recommended doses.</p>
          <p>Likelihood score: E (Unlikely cause of clinically apparent liver injury).</p>
          <p>Drug Class: <related-object source-id="livertox" document-id="MuscleRelaxants">Muscle Relaxants</related-object></p>
        </sec>
      </sec>
      <sec id="Carisoprodol.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <boxed-text position="anchor" id="Carisoprodol.BPI" orientation="portrait">
          <p>
            <bold>REPRESENTATIVE TRADE NAMES</bold>
          </p>
          <p>Carisoprodol &#x02013; Generic, Soma&#x000ae;</p>
          <p>
            <bold>DRUG CLASS</bold>
          </p>
          <p>Autonomic Agents: Muscle Relaxants, Central</p>
          <p>
            <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=carisoprodol"> COMPLETE LABELING</ext-link>
          </p>
          <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
        </boxed-text>
      </sec>
      <sec id="Carisoprodol.CHEMICAL_FORMULA_AND_STRUCT">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Carisoprodol.T1" position="anchor" orientation="portrait">
          <table>
            <thead>
              <tr>
                <th id="hd_h_Carisoprodol.T1_1_1_1_1" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Carisoprodol.T1_1_1_1_2" rowspan="1" colspan="1">CAS REGISTRY NO</th>
                <th id="hd_h_Carisoprodol.T1_1_1_1_3" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Carisoprodol.T1_1_1_1_4" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Carisoprodol.T1_1_1_1_1" rowspan="1" colspan="1">Carisoprodol</td>
                <td headers="hd_h_Carisoprodol.T1_1_1_1_2" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134970761">78-44-4</ext-link>
                </td>
                <td headers="hd_h_Carisoprodol.T1_1_1_1_3" rowspan="1" colspan="1">C12-H24-N2-O4</td>
                <td headers="hd_h_Carisoprodol.T1_1_1_1_4" rowspan="1" colspan="1">
                  <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Carisprodol_Structure.jpg" mime-subtype="jpeg" position="anchor" orientation="portrait">
                    <alt-text>Carisoprodol chemical structure</alt-text>
                  </graphic>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Carisoprodol.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 30 January 2017</p>
        <ref-list id="Carisoprodol.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Carisoprodol.R1">
            <mixed-citation publication-type="other">Zimmerman HJ. Muscle spasmolytics. In, Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd Ed. Philadelphia: Lippincott, 1999. p. 544-45.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity published in 1999; discusses dantrolene, chlorzoxazone and baclofen, but not carisoprodol).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Carisoprodol.R2">
            <mixed-citation publication-type="other">Hibbs RE, Zambon AC. Agents acting at the neuromuscular junction and autonomic ganglia. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s The pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill, 2011. p. 255-76.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Carisoprodol.R3">
            <mixed-citation publication-type="journal">Goldberg D. Carisoprodol toxicity. Military Med 1969; 134: 597-601. <annotation><p><italic toggle="yes">(Case report of patient with intentional carisoprodol overdose presented with twitching and coma requiring intubation, but ultimately recovered; no mention of liver abnormalities).</italic></p></annotation><pub-id pub-id-type="pmid">4979454</pub-id></mixed-citation>
          </ref>
          <ref id="Carisoprodol.R4">
            <mixed-citation publication-type="journal">Roth BA, Vinson DR, Kim S. Carisoprodol-induced myoclonic encephalopathy. J Toxicol Clin Toxicol 1998; 36: 609-12. <annotation><p><italic toggle="yes">(Case report of patient with carisoprodol overdose who developed coma, but had no liver abnormalities).</italic></p></annotation><pub-id pub-id-type="pmid">9776967</pub-id></mixed-citation>
          </ref>
          <ref id="Carisoprodol.R5">
            <mixed-citation publication-type="journal">Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004; 28: 140-75. <annotation><p><italic toggle="yes">(Thorough review of the pharmacology, efficacy and side effects of the muscle relaxants).</italic></p></annotation><pub-id pub-id-type="pmid">15276195</pub-id></mixed-citation>
          </ref>
          <ref id="Carisoprodol.R6">
            <mixed-citation publication-type="journal">Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther 2004; 26: 1355-67. <annotation><p><italic toggle="yes">(A review of safety and efficacy of muscle relaxants metnions that the major adverse effects of carisoprodol are drowsiness, dizziness, vertigo, ataxia, tremor, irritability and headache, and that its potential for abuse and dependence limit its usefulness for rehabilation).</italic></p></annotation><pub-id pub-id-type="pmid">15530999</pub-id></mixed-citation>
          </ref>
          <ref id="Carisoprodol.R7">
            <mixed-citation publication-type="journal">Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug-induced liver injury in the United States. Liver Transpl 2004; 10: 1018-23. <annotation><p><italic toggle="yes">(Among ~50,000 liver transplants done in the US between 1990 and 2002, 270 [0.5%] were done for drug induced acute liver failure, but none were attributed to a specific muscle relaxant).</italic></p></annotation><pub-id pub-id-type="pmid">15390328</pub-id></mixed-citation>
          </ref>
          <ref id="Carisoprodol.R8">
            <mixed-citation publication-type="journal">Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76. <annotation><p><italic toggle="yes">(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, none of which were attributed to muscle relaxants).</italic></p></annotation><pub-id pub-id-type="pmid">20949552</pub-id></mixed-citation>
          </ref>
          <ref id="Carisoprodol.R9">
            <mixed-citation publication-type="journal">Reeves RR, Burke RS, Kose S. Carisoprodol: update on abuse potential and legal status. South Med J 2012; 105: 619-23. <annotation><p><italic toggle="yes">(Review of the abuse of carisoprodol and its classification as a schedule IV class agent).</italic></p></annotation><pub-id pub-id-type="pmid">23128807</pub-id></mixed-citation>
          </ref>
          <ref id="Carisoprodol.R10">
            <mixed-citation publication-type="journal">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. Ann Hepatol 2014; 13: 231-9. <annotation><p><italic toggle="yes">(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, none were attributed to carisoprodol or other muscle relaxants).</italic></p></annotation><pub-id pub-id-type="pmid">24552865</pub-id></mixed-citation>
          </ref>
          <ref id="Carisoprodol.R11">
            <mixed-citation publication-type="journal">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-1352. <annotation><p><italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 5 [0.7%] were attributed to muscle relaxants [2 to dantrolene, and 1 each to baclofen, metaxalone and tizanidine], but none were attributed to carisoprodol).</italic></p></annotation><pub-id pub-id-type="pmid">25754159</pub-id></mixed-citation>
          </ref>
        </ref-list>
      </sec>
      <sec id="Carisoprodol.OTHER_REFERENCE_LINKS" sec-type="link-group">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Carisoprodol/AE+AND+Human%5BMH%5D+AND+(drug-induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI+OR+hepatitis,+toxic%5BMH%5D)+AND+(%222009/12/01/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)">Recent References on Carisoprodol: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Carisoprodol">Trials on Carisoprodol: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
